Status:
COMPLETED
AZD6088 Single Ascending Dose Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The aims of the study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD6088 following single ascending dose administration in healthy male and non-fertile females.
Eligibility Criteria
Inclusion
- Caucasian male and non-fertile female healthy volunteers aged ≥18 to ≤55 years with suitable veins for cannulation or repeated venipuncture.
- Clinically normal physical findings including supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by the investigator.
- Normal and suitable EEG, as judged by a neurologist
Exclusion
- History of any clinically significant disease or disorder which for instance includes CNS disorder or CV disorder.
- Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator.
- Any clinically important abnormalities in the ECG.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00931541
Start Date
June 1 2009
End Date
August 1 2009
Last Update
September 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London Bridge, Greater London, United Kingdom